News Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 16/06/2025			5-day change	1st Jan Change
161,800.00 ^KRW	+0.62%		+3.17%	-10.25%

05-27	South Korean Shares Slip on Profit-Booking; Korea Zinc Loses 4% on KFTC Probe	MT
05-27	Celltrion to Issue Nearly 8.5 Million Bonus Shares Amid Valuation Concerns	MT

Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	06-16	PU
South Korean Shares Slip on Profit-Booking; Korea Zinc Loses 4% on KFTC Probe	05-27	MT
Celltrion to Issue Nearly 8.5 Million Bonus Shares Amid Valuation Concerns	05-27	MT
Celltrion Inc To Issue 8.5 Million Bonus Shares	05-26	RE
US FDA Expands Interchangeable Status for Celltrion's Humira Biosimilar Yuflyma	05-22	MT
Celltrion's YUFLYMA® (Alalimumab-Aaty) Receives FDA Interchangeability Designation for All Its Approved Doseforms and Strengthens	05-22	CI
S.Korean shares end higher as pharma stocks jump on government's support pledge	05-21	RE
South Korea vows more policy support, including for drugmakers, as US tariffs weigh	05-21	RE
South Korean shares rise 1% as pharmaceutical stocks jump	05-21	RE
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 3, 2025.	05-20	CI
Celltrion, Inc. announces an Equity Buyback for 649,351 shares.	05-20	CI
Celltrion, Inc. authorizes a Buyback Plan.	05-20	CI
Celltrion Inc To Buy Back 100 Billion Won Worth Shares	05-19	RE
Celltrion Chairman Says US Drug Price Reform Unlikely to Impact Business	05-16	MT
Celltrion, Inc.'s Equity Buyback announced on April 3, 2025, has closed with 631,712 shares, representing 0.29% for KRW 99,566.21 million.	05-15	CI
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-15	CI
Hyundai ADM Bio Voluntary Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy	05-13	CI
South Korean shares gain over 1% on US-China trade optimism	05-12	RE
Celltrion : Investor Presentation May & June 2025	05-12	PU
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs	05-12	DJ
Celltrion To Cancel Its Own Shares Worth 98.5 Billion Won	05-12	RE
Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	04-29	AQ
Celltrion, Inc. to Present Six Abstracts in Inflammative Disease Week at 2025 Digestive Disease Week®?	04-28	CI
Celltrion, Inc. announces an Equity Buyback for 631,712 shares.	04-28	CI
Celltrion, Inc. authorizes a Buyback Plan.	04-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Filters